PatentJun 8, 2026, 08:02 AM
MediciNova Receives US Patent Allowance for Ibudilast in Glioblastoma
AI Summary
MediciNova, Inc. announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application. This patent covers the use of ibudilast (MN-166) in combination with an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for treating glioblastoma. This development is expected to strengthen the company's intellectual property position for its combination therapy development strategy, with the patent expiring no earlier than September 2042.
Key Highlights
- MediciNova received a U.S. Patent and Trademark Office Notice of Allowance.
- The patent covers ibudilast (MN-166) combined with an anti-PD-1 antibody for glioblastoma.
- This strengthens MediciNova's intellectual property for MN-166 in glioblastoma.
- Allowed claims cover multiple treatment parameters, including dosing and administration.
- The patent is expected to expire no earlier than September 2042.
- MN-166 is also in late-stage clinical development for neurodegenerative diseases.
Price Impact
More from MNOV